☀️ Narcolepsy Type 1 vs Type 2 Orexin Deficiency Simulator

Excessive Daytime Sleepiness — The Common Entry Point

Every narcolepsy diagnosis starts with irresistible daytime sleep attacks.

• 10–25: EDS onset age (typical years)
• <30 min: Sleep attack duration (brief, refreshing)
• ~1 in 2,000: Prevalence (Type 1) (US estimate)
• ~10 yrs: Diagnostic delay (average, historically)

What excessive daytime sleepiness looks like

Sudden, irresistible sleep urges strike regardless of prior rest.

Naps are often brief and subjectively refreshing.

EDS alone cannot separate type 1 from type 2 narcolepsy.

Why EDS is a nonspecific starting clue

Sleep apnea, depression, and shift work also cause EDS.

Objective testing is required before diagnosis proceeds.

MSLT and CSF testing move differentiation forward.

EDS is necessary but not sufficient — cataplexy and CSF orexin decide the subtype.

The path from symptom to subtype

Clinical history screens for cataplexy episodes next.

Polysomnography and MSLT confirm rapid REM onset.

CSF orexin-A testing finalizes the classification.

Cataplexy Assessment — The Defining Clinical Split

Cataplexy is sudden muscle weakness triggered by strong emotion.

• ~90%: Cataplexy in Type 1 (of patients)
• 0%: Cataplexy in Type 2 (by definition)
• Laughter: Common trigger (most frequent)
• Preserved: Consciousness during episode (fully aware)

What a cataplexy episode looks like

Sudden bilateral muscle weakness follows strong emotion.

Jaw sag, head drop, or full body collapse can occur.

Episodes last seconds to a few minutes.

Why cataplexy defines Type 1

Cataplexy reflects intrusion of REM muscle atonia while awake.

Its presence strongly predicts CSF orexin-A deficiency.

Absence of cataplexy points toward Type 2.

Cataplexy plus low CSF orexin-A together confirm narcolepsy Type 1.

Assessing cataplexy in the clinic

Structured interviews probe emotional triggers carefully.

Video documentation helps confirm atypical presentations.

Misdiagnosis as seizure or syncope is common.

CSF Orexin-A Testing — The Objective Biomarker

Lumbar puncture measures orexin-A directly from cerebrospinal fluid.

• <110 pg/mL: Type 1 threshold (or <1/3 normal mean)
• ~250–300: Normal CSF orexin-A (pg/mL typical)
• Very high: Test specificity (for Type 1)
• Lumbar puncture: Procedure (single sample)

How orexin-A is measured

A lumbar puncture collects cerebrospinal fluid for assay.

Radioimmunoassay quantifies orexin-A concentration precisely.

Results classify low, borderline, or normal levels.

Why this test is diagnostically powerful

Orexin-A level reflects surviving hypothalamic neuron count.

Severe loss produces unmistakably low CSF values.

Mild or no loss keeps values near normal.

CSF orexin-A below 110 pg/mL is essentially diagnostic of Type 1.

Limitations of CSF testing

Lumbar puncture is invasive and not always available.

Borderline values can occur without clear autoimmune loss.

Results are interpreted alongside cataplexy history.

Type 1 Pattern — Cataplexy With Severe Orexin Loss

Cataplexy plus CSF orexin-A below 110 pg/mL defines Type 1.

• ~90%: Neuron loss (of orexin neurons)
• <110 pg/mL: CSF orexin-A (diagnostic cutoff)
• Autoimmune: Suspected cause (T-cell mediated)
• DQB1*06:02: HLA association (strong linkage)

The autoimmune destruction model

Orexin-producing neurons are selectively attacked and lost.

Only the lateral hypothalamus population is affected.

Destruction appears irreversible once symptoms emerge.

Clinical consequences of severe loss

Cataplexy, sleep paralysis, and hallucinations often co-occur.

Nighttime sleep becomes fragmented and unstable.

Symptoms are usually lifelong and require management.

Type 1 is the clearer, more severe, and better-characterized narcolepsy subtype.

Treatment implications for Type 1

Stimulants address daytime sleepiness symptoms.

Anticataplectic drugs target REM-intrusion pathways.

Orexin receptor agonists are an emerging treatment.

Type 2 Pattern — No Cataplexy, Preserved Orexin

Without cataplexy and with normal CSF orexin-A, Type 2 applies.

• Mild or none: Neuron loss (partial at most)
• >110 pg/mL: CSF orexin-A (normal or borderline)
• Absent: Cataplexy (defining feature)
• ~10%: Conversion to Type 1 (over time, rare)

Why Type 2 differs mechanistically

Orexin neuron population remains largely intact.

Excessive sleepiness arises through less understood pathways.

Etiology is more heterogeneous than Type 1.

Diagnostic caution for Type 2

No single biomarker confirms Type 2 conclusively.

MSLT criteria and symptom history carry more weight.

A minority later develop cataplexy and reclassify.

Type 2 is a diagnosis of exclusion built on absence, not a positive biomarker.

Managing Type 2 narcolepsy

Wake-promoting agents remain the primary therapy.

Regular follow-up watches for emerging cataplexy.

Prognosis is generally milder than Type 1.